Table 2. Incidence of Common Dermatologic Toxicities of Approved EGFR Inhibitors in Selected Pivotal Studies.

Drug	Tumor	Phase	N	Regimen	Dermatologic Side Effects
Gefitinib						500mg/day	250mg/day	Placebo
Herbst et al, 2004 INTACT 2	NSCLC	3	1037	Paclitaxel + carboplatin ± gefitinib	Rash % 67.3(Gr 3/4:11.7) 54.4 (Gr 3/4 3.2) 37.5 (Gr 3/4: 1.5) Acne % 26.3 (Gr 3/4: 5.0) 19.9 (Gr 3/4: 0.9) 7.3 ( Gr 3/4: 0) Pruritis % 20.5 (Gr 3/4: 1.8) 15.2 (Gr 3/4: 0.3) 12.6 (Gr 3/4: 0.3)
Giaccone G et al, 2004 INTACT 1	NSCLC	3	1093	Cisplatin + gemcitabine ± gefitinib	Rash % 56.7 (Gr3/4:12.6) 44.5 (Gr 3/4 3.6) 21.4 (Gr 3/4: 1.1) Acne % 28.2 (Gr 3/4: 5.9) 18.2 (Gr 3/4: 1.4) 5.1 (Gr 3/4: 0.3) Pruritis % 12.6 (Gr 3/4: 2.0) 7.5 (Gr 3/4: 0.0) 12.4 (Gr 3/4: 0.0)
Kris et al, 2002 IDEAL 2 (Lead to approval)	NSCLC	2	216	Monotherapy - gefitinib (500 or 250 mg)	Grade 1/2 reversible rash
Cetuximab
Trigo et al, 2005	H & N	2	96	Cetuximab combined with platinum	Skin reactions 80% (Gr 3/4: 1%); Acne like rash 72%; Gr 3/4: 1%
Bonner et al, 2004	H & N	3	424	Combined with RT	Rash 97% overall; 34% grade 3/4
Cunningham et al	CRC	2	329	Monotherapy or with irinotecan	Acne like rash, Overall 80%; Grade 3/4 5.2% monotherapy; 9.4% in Combined
Erlotinib
Gatzemeier et al, 2004 TALENT	NSCLC	3	1172	Gemcitabine + cisplatin ± erlotinib	Grade 3/4 skin rash: 10%
Shepherd et al, 2005	NSCLC	3	731	Monotherapy	Overall rash 76%; Placebo 17%
Moore et al, 2005	Pancreas	3	569	Gemcitabine ± erlotinib	Grade 1/2 rash higher in the Erlotinib arm
Panitumumab
Peeters et al, 2006	MCC	3	463	Panitumumab + BSC(BSC = best supportive care)	6 mg/kg Q 2 wks + BSC 91%		Placebo (BSC alone) 15%

Sources: 10,22,23,24,25,26,27,28,29,30